fms-Like Tyrosine Kinase 3
"fms-Like Tyrosine Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
Descriptor ID |
D051941
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.020 D12.776.543.750.630.020 D12.776.624.664.700.114
|
Concept/Terms |
fms-Like Tyrosine Kinase 3- fms-Like Tyrosine Kinase 3
- fms Like Tyrosine Kinase 3
- Fetal Liver Kinase-2
- Fetal Liver Kinase 2
- Fetal Liver Kinase-3
- Fetal Liver Kinase 3
- CD135 Antigens
- Antigens, CD135
- CD135 Antigen
- Antigen, CD135
- Stem Cell Tyrosine Kinase 1
|
Below are MeSH descriptors whose meaning is more general than "fms-Like Tyrosine Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "fms-Like Tyrosine Kinase 3".
This graph shows the total number of publications written about "fms-Like Tyrosine Kinase 3" by people in this website by year, and whether "fms-Like Tyrosine Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2007 | 0 | 1 | 1 | 2008 | 0 | 1 | 1 | 2012 | 0 | 1 | 1 | 2014 | 1 | 0 | 1 | 2015 | 1 | 0 | 1 | 2016 | 1 | 2 | 3 | 2017 | 2 | 0 | 2 | 2019 | 0 | 1 | 1 | 2020 | 0 | 1 | 1 | 2021 | 2 | 0 | 2 | 2022 | 0 | 1 | 1 | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "fms-Like Tyrosine Kinase 3" by people in Profiles.
-
Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2023 02 01; 108(2):457-471.
-
Park HJ, Gregory MA, Zaberezhnyy V, Goodspeed A, Jordan CT, Kieft JS, DeGregori J. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. Elife. 2022 10 19; 11.
-
Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Th?lken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, M?nch C, Brandts CH. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022 10; 36(10):2396-2407.
-
Droho S, Perlman H, Lavine JA. Dendritic cells play no significant role in the laser-induced choroidal neovascularization model. Sci Rep. 2021 08 26; 11(1):17254.
-
Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 05; 35(5):1279-1290.
-
Tufa DM, Shank T, Yingst AM, Trahan GD, Shim S, Lake J, Woods R, Jones K, Verneris MR. Prolactin Acts on Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage. Sci Rep. 2020 04 14; 10(1):6335.
-
Pandita A, Ramadas P, Poudel A, Saad N, Anand A, Basnet A, Wang D, Middleton F, Gilligan DM. Differential expression of miRNAs in acute myeloid leukemia quantified by Nextgen sequencing of whole blood samples. PLoS One. 2019; 14(3):e0213078.
-
Schaenzer AJ, Wlodarchak N, Drewry DH, Zuercher WJ, Rose WE, Ferrer CA, Sauer JD, Striker R. GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against ?-Lactam-Resistant Staphylococcus aureus. ACS Infect Dis. 2018 10 12; 4(10):1508-1518.
-
Stansfield LC, Pollyea DA. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. Pharmacotherapy. 2017 12; 37(12):1586-1599.
-
Gregory MA, Nemkov T, Reisz JA, Zaberezhnyy V, Hansen KC, D'Alessandro A, DeGregori J. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp Hematol. 2018 02; 58:52-58.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|